Raymond James & Associates Boosts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)


Raymond James & Associates lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating) by 16.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,403 shares of the company’s stock after buying an additional 6,176 shares during the period. Raymond James & Associates owned approximately 0.06% of CRISPR Therapeutics worth $1,764,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Profund Advisors LLC raised its stake in CRISPR Therapeutics by 2.7% during the fourth quarter. Profund Advisors LLC now owns 8,733 shares of the company’s stock worth $355,000 after purchasing an additional 227 shares during the period. E Fund Management Co. Ltd. raised its stake in CRISPR Therapeutics by 3.6% during the third quarter. E Fund Management Co. Ltd. now owns 7,113 shares of the company’s stock worth $465,000 after purchasing an additional 245 shares during the period. Signaturefd LLC raised its stake in CRISPR Therapeutics by 14.3% during the third quarter. Signaturefd LLC now owns 2,025 shares of the company’s stock worth $132,000 after purchasing an additional 253 shares during the period. Kistler Tiffany Companies LLC raised its stake in CRISPR Therapeutics by 51.6% during the third quarter. Kistler Tiffany Companies LLC now owns 782 shares of the company’s stock worth $51,000 after purchasing an additional 266 shares during the period. Finally, EverSource Wealth Advisors LLC raised its stake in CRISPR Therapeutics by 2,440.0% during the third quarter. EverSource Wealth Advisors LLC now owns 381 shares of the company’s stock worth $25,000 after purchasing an additional 366 shares during the period. 71.51% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CRSP has been the topic of a number of research analyst reports. Sanford C. Bernstein initiated coverage on shares of CRISPR Therapeutics in a research note on Tuesday, March 21st. They issued a “market perform” rating and a $44.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, April 20th. William Blair initiated coverage on shares of CRISPR Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $75.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of CRISPR Therapeutics in a report on Thursday, April 13th. They set an “overweight” rating and a $72.00 price target for the company. Finally, Credit Suisse Group lowered their price target on shares of CRISPR Therapeutics from $78.00 to $65.00 and set a “neutral” rating for the company in a report on Wednesday, February 22nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics has a consensus rating of “Hold” and a consensus target price of $74.89.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 25,000 shares of the firm’s stock in a transaction on Tuesday, April 25th. The stock was sold at an average price of $50.67, for a total value of $1,266,750.00. Following the sale, the chief executive officer now directly owns 387,377 shares in the company, valued at $19,628,392.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.10% of the stock is currently owned by company insiders.

CRISPR Therapeutics Stock Down 0.0 %

Shares of NASDAQ:CRSP opened at $64.63 on Wednesday. CRISPR Therapeutics AG has a 52-week low of $38.94 and a 52-week high of $86.95. The company has a 50 day moving average of $53.35 and a two-hundred day moving average of $50.96. The company has a market capitalization of $5.10 billion, a price-to-earnings ratio of -9.62 and a beta of 1.71.

CRISPR Therapeutics (NASDAQ:CRSPGet Rating) last released its quarterly earnings data on Monday, May 8th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.97. The firm had revenue of $100.00 million during the quarter, compared to the consensus estimate of $24.33 million. CRISPR Therapeutics had a negative net margin of 516.43% and a negative return on equity of 26.64%. The firm’s revenue was up 10538.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.32) earnings per share. On average, equities analysts anticipate that CRISPR Therapeutics AG will post -6.61 earnings per share for the current year.

CRISPR Therapeutics Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Recommended Stories

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPGet Rating).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for CRISPR Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CRISPR Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Read more here: Source link